Compare Ascendis Pharma A/S (ASND) vs Genuine Parts Company (GPC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Genuine Parts Company — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Genuine Parts Company trades at $125.62 (market cap $17.29B). The key difference: Ascendis Pharma A/S and Genuine Parts Company are close in size by market cap, and Genuine Parts Company pays a 3.38% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GPC | |
|---|---|---|
Market Cap | $17.74B | $17.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $149.26 |
52-Week Low | $163.32 | $92.47 |
Enterprise Value | $18.11B | $23.50B |
Dividend Yield | — | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
GPC trades at $125.62, up 1.09% with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue grew to $24.3B in 2025, though net margins compressed to 0.24%. Analyst consensus is mixed with 43% buy ratings and a $133 price target. Recent news highlights GPC's 70-year dividend growth streak and upcoming Q2 2026 earnings report on July 21, 2026.
GPC offers income stability with its Dividend King status but faces profitability challenges. The stock trades near analyst targets with moderate upside potential. Key risks include margin pressure from rising costs and competitive threats in auto parts distribution. Institutional sentiment remains cautiously optimistic given the stable dividend history amid earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
